NRX Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. Co. is developing therapeutics based on its N-methyl-D-aspartate (NMDA) platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and post-traumatic stress disorder (PTSD). Co. has two lead compounds, NRX-100, a proprietary presentation of ketamine and NRX-101, a fixed-dose combination of D-cycloserine (DCS) and lurasidone. Co. is developing NRX-101, a Food and Drug Administration (FDA)-designated investigational therapy for suicidal treatment-resistant bipolar depression and chronic pain. We show 22 historical shares outstanding datapoints in our NRXP shares outstanding history coverage, used to compute NRXP market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing NRXP market cap history over the course of time is important for investors
interested in comparing NRXP's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of NRXP versus a peer is one thing; comparing
NRXP market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like NRXP can fluctuate over the course of history.
With this page we aim to empower investors researching NRXP by allowing them to research the NRXP market cap history. |
Free NRXP Email Alerts:
Video: The Importance of Market Cap
